Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/fr75XK21L1 https://t.co/Hhax7po7vV
Links:
Efficacy and Safety of Upadacitinib in Patients with Giant Cell Arteritis (SELE…
https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-in-patien…
16-11-2024